Medical specialists from Belgium tagged as investigators in clinical trials studying Hepatitis C

Total 12 results

Annelies Posen, dr.
Seen in:
- Tongeren, AZ Vesalius
Trials:
- NCT04251572 (Principal Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of
Boris Bastens, prof. dr.
Seen in:
- Liège, CHC Saint-Josephe, Liège
Trials:
- NCT04251572 (Principal Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of
Catharina Mathëi, MD
Seen in:
- Antwerp, Free Clinic Antwerp
Trials:
- NCT04251572 (Principal Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of
Christophe Van Steenkiste, dr.
Seen in:
- Gent, AZ Maria-Middelares
Trials:
- NCT04251572 (Principal Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of
Dana Busschotes, drs.
Seen in:
- Diepenbeek, Hasselt University
Trials:
- NCT04717856 (Sub-Investigator)
Conditions:
- Hepatitis C;
- Drug Use
Dana Busschots, drs.
Seen in:
- Genk, Ziekenhuis Oost-Limburg
Trials:
- NCT04251572 (Sub-Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of
Eefje Dercon, nurse
Seen in:
- Genk, Ziekenhuis Oost-Limburg
Trials:
- NCT04251572 (Sub-Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of
Filip Janssens, dr.
Seen in:
- Hasselt, Jessa Ziekenhuis
Trials:
- NCT04251572 (Principal Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of
Jean-Pierre Mulkay, prof. dr.
Seen in:
- Bruxelles, CHU Saint-Pierre
Trials:
- NCT04251572 (Principal Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of
luc Van Den Bergh, dr.
Seen in:
- Sint-Truiden, Sint-Trudo ziekenhuis
Trials:
- NCT04251572 (Principal Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of
Rita Verrando, dr.
Seen in:
- Hasselt, CAD Limburg
Trials:
- NCT04251572 (Principal Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of
Stefan Bourgeois, dr.
Seen in:
- Antwerp, ZNA Stuivenberg
Trials:
- NCT04251572 (Principal Investigator)
Conditions:
- Drug Use;
- Hepatitis C Virus Infection, Response to Therapy of

Clinical Trials on Hepatitis C

Tripep AB
Inovio Pharmaceuticals

Unknown

Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients

Chronic Hepatitis C Virus Infection

Sweden
Hadassah Medical Organization
XTL Biopharmaceuticals

Withdrawn

Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers

Chronic Hepatitis C Virus Infection

Israel
Hadassah Medical Organization

Unknown

Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT

Chronic Hepatitis C Virus Infection

Israel
AbbVie

Completed

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
AbbVie (prior sponsor, Abbott)

Completed

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)

United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
Trek Therapeutics, PBC

Completed

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral Infection

United States, New Zealand
Trek Therapeutics, PBC

Completed

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral Infection

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)

Hepatitis C Virus | Chronic Hepatitis C Virus
AbbVie (prior sponsor, Abbott)

Completed

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States
Beni-Suef University

Completed

ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

Chronic Hepatitis C Virus Infection

Egypt

Medical specialists from Belgium tagged as investigators in clinical trials studying Hepatitis C

Clinical Trials on Hepatitis C

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations